Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

Affiliations

¹ Departments of Neurology, Neurosurgery and Pediatrics, Lucile Packard Children's Hospital at Stanford, Stanford, California; Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada; Departments of Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington; Departments of Pediatrics, University of Colorado and Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Denver, Colorado; Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington D.C.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Pediatric Hematology/Oncology, Riley Children's Hospital, Indianapolis, Indiana; Department of Pediatrics, Texas Children's Hospital, Houston, Texas; Lady Cilento Children's Hospital, Brisbane, Australia; Princess Margaret Hospital for Children and Telethon Kid's Institute, Subiaco, Australia; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Tabitha Cooney et al. Neuro Oncol. 2017.

. 2017 Sep 1;19(9):1279-1280.

doi: 10.1093/neuonc/nox107.

¹ Departments of Neurology, Neurosurgery and Pediatrics, Lucile Packard Children's Hospital at Stanford, Stanford, California; Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada; Departments of Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington; Departments of Pediatrics, University of Colorado and Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Denver, Colorado; Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington D.C.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Pediatric Hematology/Oncology, Riley Children's Hospital, Indianapolis, Indiana; Department of Pediatrics, Texas Children's Hospital, Houston, Texas; Lady Cilento Children's Hospital, Brisbane, Australia; Princess Margaret Hospital for Children and Telethon Kid's Institute, Subiaco, Australia; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.

No abstract available

References

1. Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Brain stem tumors in children and adolescents: single institutional experience. Childs Nerv Syst. 2013;29(8):1321–1331. - PubMed
1. Salloum R, DeWire M, Lane A et al. . Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol. 2015;121(3):591–598. - PubMed
1. Vallero SG, Bertin D, Basso ME, Pittana LS, Mussano A, Fagioli F. Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience. Childs Nerv Syst. 2014;30(6):1061–1066. - PubMed
1. Wolffe JE, Rytting ME, Vats TS et al. . Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106(2):391–397. - PMC - PubMed
1. Packer RJ. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr Neurosurg. 1996;24(4):211–216. - PubMed